Point72 (DIFC)’s Edgewise Therapeutics EWTX Stock Holding History

Point72 (DIFC)’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,889	Closed	-$184K	–	1786
2024 Q4	$184K	Buy	+6,889	New	+$219K	0.01%	886

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Point72 (DIFC)'s EWTX Position: Q1 2025 in Review

Point72 (DIFC) sold out of Edgewise Therapeutics (EWTX) in Q1 2025, closing a stake of 6,889 shares — an estimated $184K sold.

Point72 (DIFC) first reported a position in EWTX in Q4 2024 and held it in 1 quarter. The position peaked at $184K in Q4 2024. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

Point72 (DIFC) reported no remaining Edgewise Therapeutics position as of Q1 2025 after selling out during the quarter.
Point72 (DIFC) sold 6,889 Edgewise Therapeutics shares in Q1 2025, an estimated $184K.
Point72 (DIFC) first reported a position in Edgewise Therapeutics in Q4 2024 and held it in 1 quarter.
Point72 (DIFC)'s Edgewise Therapeutics position peaked at $184K in Q4 2024.
192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.